Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take over
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie Kim, the current president of Takeda’s US business unit, will succeed Weber in June...
View ArticleHow Define Ventures thinks health tech startups will exit in 2025
Define Ventures has its eye on around 20 or so health tech startups that it thinks will go public or be bought up over the next few years. The startups are part of what Define ...
View ArticleTectonic gets Phase 1b win in heart condition where Eli Lilly recently failed
A Phase 1b readout in a specific heart condition is causing an earthquake for one newly public biotech. Tectonic Therapeutic on Thursday morning reported the successful result of its study testing ...
View ArticleIronwood's layoffs; Shionogi’s RSV pill succeeds in Phase 2
Plus, news about Immunome, Deerfield, Switch Therapeutics, ReCode Therapeutics, Atara Biotherapeutics and Genfit: Ironwood halves workforce: The Boston drugmaker is letting go of about 50% of its...
View ArticleCargo Therapeutics cuts lead CAR-T program, 50% of staff
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result. The San...
View ArticleBright Green budgets $3.5B for new builds; European Commission opens...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. API producer Bright Green is investing $3.5 billion to build...
View ArticleTakeda scraps programs as it raises full-year guidance
Several months into a multiyear quest to “rigorously prioritize" its pipeline, Takeda is cutting a handful of programs. The company revealed the changes on Thursday in its third-quarter earnings...
View ArticleRentschler exits cell and gene business due to low demand, will prioritize...
German CDMO Rentschler Biopharma is closing down its cell and gene therapy operations and shuttering a facility in the UK, which could affect up to 30 employees, a company spokesperson told Endpoints...
View ArticleHims is making its Super Bowl debut with an ad that goes straight for pharma
The telehealth startup Hims & Hers comes out swinging against pharmaceutical companies in a provocative new ad slated to air during the Super Bowl. The minute-long spot blames the weight ...
View ArticleBlackstone secures $1.6B so far for new life sciences fund targeted at $5B+
The world's biggest alternative asset manager is further cementing itself in the life sciences industry with another fund dedicated to drug development. Blackstone confirmed on its earnings call on...
View ArticleFDA approves Axsome's acute migraine treatment after 2022 rejection
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for the drug on Thursday to treat acute migraines with or without aura. The drug,...
View ArticleRegeneron wins appeals court orders backing halt on Eylea biosimilars
Two biotech companies failed to reverse orders barring them from selling biosimilars of Regeneron’s eye disease drug Eylea in rulings from a federal appeals court. The US Court of Appeals for the...
View ArticleVertex's non-opioid pain drug Journavx is approved by FDA
The FDA approved Vertex’s non-opioid drug for moderate to severe acute pain, bringing to market the first in a new class of alternatives to painkillers. The drug, known as suzetrigine, will have the...
View ArticleMaze and Metsera biotech IPOs to begin trading Friday
Obesity drug developer Metsera and kidney disease biotech Maze Therapeutics priced their Nasdaq IPOs on Thursday evening. Metsera {$MTSR} will raise $275 million and Maze {$MAZE} will raise $140...
View ArticleNovartis claims best earnings in years, validating shift to pure-play strategy
Novartis said Friday that last year was one of its "strongest" financial performances in its history following a multiyear reorg as a pure-play pharma company, bolstered by steady ...
View ArticleRoche separates CFO, informatics posts; Lilly execs land at Kailera, Neurocrine
→ Wafaa Mamilli’s first day as chief digital technology officer for Roche will be Feb. 10, according to a release on the eve of the Swiss pharma’s
View ArticleAbbVie raises Skyrizi and Rinvoq estimates, predicts $31B in 2027 sales
The loss of Humira exclusivity was long expected to be a blow to AbbVie’s immunology dominance, but the Skyrizi-Rinvoq tandem keeps outpacing expectations. In its fourth-quarter and full-year 2024...
View ArticleCelltrion looks to buy US facilities to sidestep potential Trump tariffs
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President Donald Trump’s potential tariffs on foreign-made pharmaceuticals. Trump is...
View ArticleDaiichi Sankyo taps new CEO, aims to build up ADC franchise
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer. Before starting that role in 2023 ...
View ArticleAstraZeneca scraps plan to expand UK vaccine site
AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed funding for the project, a company spokesperson confirmed to Endpoints...
View ArticleEngland agrees to pay for Vertex’s sickle cell disease gene therapy
Vertex Pharmaceuticals and the National Health Service in England have reached a payment deal making the gene-edited therapy Casgevy available to certain people with sickle cell disease. The NHS said...
View ArticleGenentech joins suits against STD clinics over 340B discounts
Genentech is the latest drugmaker to sue the federal government over STD clinics it says are wrongfully receiving discounts through the federal 340B program. The company claimed Friday that several...
View ArticleAbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up...
The reports of AbbVie’s demise have been greatly exaggerated. Gone are the worries of Humira competition and its monumental patent cliff. The “lack of a shiny object” in the pipeline is a ...
View ArticleRFK Jr. continues to evade questions on vaccines and autism
Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines contribute to the development of autism. And in written responses to ...
View Article